logo-loader

End of day, week, month and thankfully of the quarter – TGIF

Last updated: 16:05 29 Jun 2012 BST, First published: 20:05 29 Jun 2012 BST

no_picture_pai

The 6 W’s: Who, what, where, when, why and what of it

 

Mid-Day: The NASDAQ is UP +66.84 (+2.35%) to 2,816.33 while the Dow is way … UP +213.12 (+1.69%) to 12,815.38.

 

Market Commentary:Stocks are holding their gains on the … final trading day of Q2 … as a surprise agreement by EU leaders to help the region’s struggling banks overshadowed a disappointing consumer sentiment report.

 

Today’s Gospel:   RegMed stocks moved … slightly … higher in a lackluster trading on Friday, as traders reacted positively to the latest news out of the EU and welcomed … market appreciation on a pre-holiday week. The NASDAQ showed a strong move to the upside … having ended the previous session in the red.

 

I am still watching and measuring the impact of ASTM’s “Common Stock Exchange” … as I believe it could be a precedent for other RegMed universe companies to execute during these “dark” days of summer.

 

Mid-day … trading had … Dendreon (DNDN) is the leader … followed by Cryo-Cell (OTC BB: CCEL), BioTime (Amex: BTX), Verastem (VSTM), and Cytori (CYTX) …

 

My continuing mantra … we have movement – but, not quite momentum!  The CBOE Volatility Index <options activity and fear gauge> tumbled 10% to below … 18 <from above 20>.  The sector has even green (ups) … and reds (downs) but, 4-5 fluctuating black (flats).

 

My favorites:

  • Aastrom (ASTM) is down -$0.05 but, minimal … at $2.13 …with a … mid-day range of $2.12 – $2.19 from yesterday’s $2.14 – $2.19 with … larger volume … of 82K so, far  <versus 92.3K> shares. MLV Equity raises  price target … to $8.50 from $7.50 reiterating BUY rating  

 

  • Cytori (CYTX) is UP +$0.04 or +1.52% at $2.67 … in a trading range of $2.59 – $2.74 from yesterday’s $2.58 -$2.74 with …   trading of 145K so, far <versus 178.8 >;

 

  • Osiris (OSIR) is … DOWN … on profit taking  -$0.62 or -5.25% to $11.18 … with a increasing day’s range of $11.00 – $12.48 from yesterday’s  $11.10 – $12.47 after some big swings  with lower so, far volume of 358K <versus 175.8; sharescompared to the previous of 1.45M>;

 

  • NeoStem (Amex: NBS) is UP +$0.025 or +5.43% at $0.495 … in a day’s range of $0.47 -$0.50 … from yesterday’s $0.44 -$0.47 with 479K volume so far <versus 550K>.

 

Upward moves: 

Downward moves:

Flat:

  • Brainstorm (OTC BB: BCLI),
  • BioLife Solutions (OTC BB: BLFS),
  • Bioheart (OTC BB: BHRT),
  • Tengion (TNGN).

 

EconoDrama: Consumer sentiment dipped to 73.2 in June, according to the Thomson Reuters/University of Michigan’s survey, hitting its lowest level this year. Economists expected a reading of 74.1, unchanged from the preliminary figure.  Consumer spending was flat in May for the first time in 5 months, according to the Commerce Department, while income rose 0.2%.  The pace of business activity in the Midwest edged up to 52.9 in June from 52.7 in May, according to the Institute for Supply Management-Chicago’s business barometer. A reading above 50 indicates expansion in the regional economy.

 

What’s new in the regenerative medicine/stem cell market … see: www.scimitarequity.com/blog

 

Analysis: Ruling reduces uncertainty for biotech and Pharma: The Supreme Court’s decision to uphold the health care law greatly benefits the pharmaceutical industry by reducing risk and uncertainty that would have come with reversal, Moody’s analyst Michael Levesque said. The ruling also means that drug makers face having to pay $80 billion in rebates and fees over 10 years. Canceling part or all of the law would have meant reopening proposals that drug makers managed to avoid during drafting of the Patient Protection and Affordable Care Act. So … from the same people who rated CDOs and more … we are not stupid … say something we don’t know!!

 

BIO reacts to ruling on Affordable Care Act:  BIO will collaborate on the implementation of the Affordable Care Act to help the biotech industry develop “lifesaving cures and other medical breakthroughs,” said BIO President and CEO Jim Greenwood in reaction to the Supreme Court’s decision to uphold the health care law. Greenwood said BIO will work with the FDA in the implementation of the bio-similar pathway under the act. “We will work to ensure that biotech researchers can continue to address the diseases of today while conducting the research and investment required to develop the advanced medicines and cures of tomorrow,” he said.  Such non-words … another lap dance, please!!

 

 We are getting closer to: E-News, Actionable Intelligence, Data Analytics and Research – So catch the wave as we are about to launch the new … RegMed …NEWS PORTAL!! The countdown is days away … after the 4th of July.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 22 minutes ago